A lipidomics analysis from the randomised EmDia trial finds empagliflozin remodels plasma lipids in type 2 diabetes, raising beneficial LPCs but also harmful ceramides. PICO summary and commentary.
Browsing: SGLT2 Inhibitors
A phase-3 secondary analysis finds enavogliflozin lowers leptin independent of weight in type 2 diabetes, while the adiponectin rise was weight-dependent. PICO summary and commentary.
The 4-year DAPAHEART follow-up finds dapagliflozin raises coronary flow reserve by 34% and reduces epicardial fat, apparently independent of weight loss. PICO summary and commentary.
A prespecified DARE-19 analysis found dapagliflozin was safe and well tolerated in hospitalised COVID-19 patients regardless of type 2 diabetes status, with no demonstrated efficacy benefit. PICO summary and expert commentary.
A double-blind RCT finds empagliflozin gives broader cardiometabolic benefit than sitagliptin or metformin as add-on therapy in type 2 diabetes. PICO summary and commentary.
A DAPA-MI subanalysis finds dapagliflozin reduces new-onset diabetes after heart attack regardless of glucose or BMI, with most symptom benefit in prediabetes. PICO summary and commentary.
A mechanistic randomized trial found empagliflozin reduced total-body norepinephrine turnover at 1 day and 12 weeks even as hepatic glucose production rose, with the two changes inversely correlated. PICO summary and expert commentary.
A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.
A mechanistic trial finds dapagliflozin plus exenatide augments beta-cell function and insulin sensitivity more than either alone in type 2 diabetes. PICO summary and commentary.